Oncogenic alternative splicing switch of pace4 in cancer
AssigneeSociete De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et Humaine
InventorsRobert DAY, Frédéric COUTURE, Robert SABBAGH
Life of this patent
Estimating the term…
Abstract
It is provided a tumor promoting alternative splicing isoform of PACE4, named PACE4-alt CT, analytes specifically binding to PACE4-alt CT, such as antibodies, and use of same for detecting a cancer, such as prostate cancer. It is also provided a method treating a cancer in a patient comprising administering an inhibitor of PACE4-altCT to a patient in need thereof and a kit comprising an analyte specific reagent specifically binding to PACE4-altCT for detecting a cancer.
Claims27
1:
- A method for detecting a cancer in a subject comprising the steps of:
- a) obtaining a biological sample from the subject;
- b) contacting an analyte specific reagent specifically binding to PACE4-altCT with the biological sample under conditions so as to allow the formation of an analyte-PACE4-altCT complex;
- and
- c) detecting said cancer by detecting the analyte-PACE4-altCT complex in said biological sample.
2-3. (canceled)
4:
- The method of claim 1, further comprising the step of detecting the presence of PACE4-FL in said biological sample and calculating a ratio of PACE4-altCT/PACE4-FL wherein a ration of above 2 is indicative of the presence of said cancer.
5:
- The method of claim 1, wherein the sample is a blood sample, urine, a tissue specimen, a biopsy needle washes, or circulating cells.
6:
- The method of claim 1, wherein the analyte is an antibody, a peptide, a primer or a probe.
7-8. (canceled)
9:
- The method of claim 6, wherein said antibody specifically binds to SEQ ID NO:
- 9.
10:
- The method of claim 6, wherein said antibody specifically binds to an epitope comprising the amino acid sequence set forth in any one of SEQ ID NOs:
- 18, 23, 24, 25, and 26.
(canceled)
12:
- The method of claim 6, wherein the probe is an oligonucleotide or a siRNA molecule.
13:
- The method of claim 6, wherein said probe specifically binds to a nucleotide sequence comprising SEQ ID NOs:
- 5 or 6.
14:
- The method of claim 12, wherein said siRNA comprises the nucleotide sequence set forth in SEQ ID NOs:
- 10, 11, 12, 13, 14, 15 or 16.
15-18. (canceled)
19:
- The method of claim 1, wherein said cancer is in at least one of lungs, thyroid, adrenals, testis, endometrium, pancreas, oesophagus, prostate, ovary, liver, breast, colon, stomach, kidney, bladder, brain, cervix, and lymphoid tissues.
20:
- The method of claim 19, wherein said cancer is a prostate cancer.
21-35. (canceled)
36:
- An antibody specifically binding to PACE4-altCT.
37-38. (canceled)
39:
- The antibody of claim 36, wherein said antibody specifically binds to SEQ ID NO:
- 9.
40:
- The antibody of claim 36, wherein said antibody specifically binds to an epitope comprising the amino acid sequence set forth in any one of SEQ ID NOs:
- 18, 23, 24, 25, and 26.
41:
- The antibody of claim 36, for detecting and/or treating cancer.
42:
- A method of treating a cancer in a patient comprising administering an inhibitor of PACE4-altCT to a patient in need thereof.
43-79. (canceled)
80:
- The method of claim 42, wherein said inhibitor of PACE4-altCT is an antibody as defined in claim 36.
81:
- The method of claim 42, wherein said inhibitor of PACE4-altCT is a probe as defined in claim 13 or an siRNA as defined in claim 14.
82:
- The method of claim 42, wherein said cancer is in at least one of lungs, thyroid, adrenals, testis, endometrium, pancreas, oesophagus, prostate, ovary, liver, breast, colon, stomach, kidney, bladder, brain, cervix, and lymphoid tissues.
83:
- The method of claim 42, wherein said cancer is a prostate cancer.
Dependencies are inferred from the claim text.